Navigation Links
NIH-funded study connects gene variant to response to asthma drugs
Date:9/26/2011

A genetic variant may explain why some people with asthma do not respond well to inhaled corticosteroids, the most widely prescribed medicine for long-term asthma control. Researchers found that asthma patients who have two copies of a specific gene variant responded only one-third as well to steroid inhalers as those with two copies of the regular gene.

This genome-wide association study, funded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, analyzed data from over 1,000 people enrolled in five separate clinical trials that studied different steroid treatments for asthma.

The study was also funded by the National Human Genome Research Institute and the NIH Pharmacogenomics Research Network. The results will appear in the Sept. 26 online edition of the New England Journal of Medicine.

"This finding helps to explain the genetic basis for the long-standing observation that some people do not respond well to what is a common asthma treatment," said Susan Shurin, M.D., acting director of the NHLBI. "The study illustrates the importance of research examining the relationship between genetic makeup and response to therapy for asthma, and underscores the need for personalized treatment for those who have it."

Asthma is a complex inflammatory disease that affects over 22 million people in the United States and roughly 300 million people worldwide. Many factors can influence how severely the disease affects people and how well they respond to treatments. Poor response to inhaled corticosteroids (ICS) often runs in families, suggesting that genetics plays a role in how people respond to asthma treatments.

The study first conducted a genome-wide scan of the DNA of children enrolled in the Childhood Asthma Management Program and of their parents. The genomic scan uncovered a variant in a gene called GLCCI1 that appeared to be associated with poor ICS response. Study researchers then verified this association in 935 additional people with asthma, both children and adults, enrolled in four independent ICS studies. Most of the participants in these studies were white; the results may not be applicable to persons of other ethnicities.

In this study, people carrying two copies of the GLCCI1 variant were more than twice as likely to respond poorly to ICS treatment as participants with two copies of the regular GLCCI1 gene. Those who responded poorly had an average of one-third the level of lung improvement following inhaler treatment as did people with two regular copies of the gene.

About 1 in 6 study participants had two copies of the GLCCI1 variant, which is thought to work in conjunction with other genetic and environmental factors to affect response to ICS.

More studies will be needed to understand how GLCCI1 operates in the lungs and to explore whether it contributes to response in patients of other ethnic groups.


'/>"/>

Contact: NHLBI Communications Office
nhlbi_news@nhlbi.nih.gov
301-496-4236
NIH/National Heart, Lung and Blood Institute
Source:Eurekalert

Related biology news :

1. NIH-funded researchers discover genetic link to mesothelioma
2. NIH-funded research network to explore oil spill health effects
3. Rare gene glitch may hold clues for schizophrenia -- NIH-funded study
4. LSU researcher participates in NIH-funded study ushering in the age of personal genomics
5. NIH-funded scientists sequence genomes of lyme disease bacteria
6. NIH-funded studies aim to prevent, treat childhood obesity
7. NIH-funded researchers sequence exomes of 12 people
8. Study puts a new spin on ibuprofens actions
9. University of Arizona to study human-fire-climate interactions
10. Aquarium fishes are more aggressive in reduced environments, a new study finds
11. Harvard School of Public Health awarded $20 million CDC grant to study HIV prevention in Botswana
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2016)... SAN JOSE, Calif. , Jan. 20, 2016 ... leading developer of human interface solutions, today announced ... touch controller solution for wearables and small screen ... appliances such as printers. Supporting round and rectangular ... the S1423 offers excellent performance with moisture on ...
(Date:1/13/2016)... 13, 2016 ... of the  "India Biometrics Authentication & ... (2015-2020)"  report to their offering.  ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ...
(Date:1/8/2016)... Connecticut , January 8, 2016 ... m-commerce market and WorldVentures ® , a privately held ... and an Inc. 5000 fastest-growing company announced ... strategic investment of $2 million in Nxt-ID to develop ... based on Nxt-ID,s Wocket ® , a unique smart ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election in November ... Business Conference will bring together over 500 top healthcare leaders for a night and ... The conference, organized by MBA students of the University of Pennsylvania’s Wharton School, will ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... Tunnell Consulting, ... Based in Paris, he will focus on acquiring new accounts and work closely ... , “Fred brings to our European clients more than 15 years ...
(Date:2/9/2016)... This market research report on the global ... of the market in terms of revenue (USD Million). ... the manufacture of microbiology culture media and related products. ... snapshot providing the overall information of various market segments ... also provides the overall information and data analysis of ...
(Date:2/8/2016)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... companies in the TSX Venture 50 TM . ... TSX Venture Exchange, in each of five major industry sectors ... life sciences, diversified industries and technology – based on a ... market cap growth, trading volume and analyst coverage. All data ...
Breaking Biology Technology: